It was recently reported that the secretion of HSP90 by breast CSCs is required for cancer-related signaling pathways and breast tumor xenograft growth in mice [109]; inhibiting the HSP90 secretion and/or extracellular HSP90 functions was therefore suggested as a potential approach to CSC-based therapy of cancer. This evidence concerns the gene HSP90AA1 and breast neoplasm.